Abstract:Few inhibitors exist for CD38, a multifunctional enzyme catalyzing the formation and metabolism of the Ca-mobilizing second messenger cyclic adenosine 59-diphosphoribose (cADPR). Synthetic, non-hydrolyzable ligands can facilitate structure-based inhibitor design. Molecular docking was used to reproduce the crystallographic binding mode of cyclic inosine 59-diphosphoribose (N1-cIDPR) with CD38, revealing an exploitable pocket and predicting the potential to introduce an extra hydrogen bond interaction with Asp-155. The purine C-8 position of N1-cIDPR (IC50 276 mM) was extended with an amino or diaminobutane group and the 8-modified compounds were evaluated against CD38-catalyzed cADPR hydrolysis. Crystallography of an 8-amino N1-cIDPR:CD38 complex confirmed the predicted interaction with Asp-155, together with a second H-bond from a realigned Glu-146, rationalizing the improved inhibition (IC50 56 mM). Crystallography of a complex of cyclic ADP-carbocyclic ribose (cADPcR, IC50 129 mM) with CD38 illustrated that Glu-146 hydrogen bonds with the ligand N6-amino group. Both 8-amino N1-cIDPR and cADPcR bind deep in the active site reaching the catalytic residue Glu-226, and mimicking the likely location of cADPR during catalysis. Substantial overlap of the N1-cIDPR ‘‘northern’’ ribose monophosphate and the cADPcR carbocyclic ribose monophosphate regions suggests that this area is crucial for inhibitor design, leading to a new compound series of N1-inosine 59-monophosphates (N1-IMPs). These small fragments inhibit hydrolysis of cADPR more efficiently than the parent cyclic compounds, with the best in the series demonstrating potent inhibition (IC50 = 7.6 mM). The lower molecular weight and relative simplicity of these compounds compared to cADPR make them attractive as a starting point for further inhibitor design. Citation: Moreau C, Liu Q, Graeff R, Wagner GK, Thomas MP, et al. (2013) CD38 Structure-Based Inhibitor Design Using the N1-Cyclic Inosine 59-Diphosphate Ribose Template. PLoS ONE 8(6): e66247. doi:10.1371/journal.pone.0066247 Editor: Eugene A. Permyakov, Russian Academy of Sciences, Institute for Biological Instrumentation, Russian Federation Received March 11, 2013; Accepted May 2, 2013; Published June 19, 2013 Copyright: 2013 Moreau et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: This research was supported by the Wellcome Trust through Project Grant No 084068 and Programme Grant 082837 (to BVLP) and by Hong Kong General Research Fund Grants 769107, 768408, 769309, and 770610 (to HCL) and by National Institutes of Health Grant RR01646 (to QH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no competing interests exist. * E-mail: V.L.Potter@bath.ac.uk ¤a Current address: New York Structural Biology Center, Brookhaven National Laboratory, Upton, New York, United States of America ¤b Current address: Department of Physiology, University of Hong Kong, Hong Kong, China ¤c Current address: Institute of Pharmaceutical Science, King’s College London, London, United Kingdom

2-Substituted thienotetrahydropyridine derivatives: Allosteric ectonucleotidase inhibitors

Synthesis and structure-activity relationships of ticlopidine derivatives and analogs as inhibitors of ectonucleotidase CD39

Targeting Thymidine Phosphorylase With Tipiracil Hydrochloride Attenuates Thrombosis Without Increasing Risk of Bleeding in Mice

Cleavable Novel Thienopyridine Derivatives as Potent Antithrombotic Agents

ADP receptors--targets for developing antithrombotic agents.

Dihydropyrimidone Derivatives as Thymidine Phosphorylase Inhibitors: Inhibition Kinetics, Cytotoxicity, and Molecular Docking

Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents

Synthesis and Biological Evaluation of Novel Thiadiazole Derivatives as Antiplatelet Agents

Identification, Characterization, and Inhibition of the Platelet ADP Receptors

The Synthesis of Purine Derivatives and Its Inhibitory Activity on CD38 NADase

Cd38 Structure-Based Inhibitor Design Using the N1-Cyclic Inosine 5 '-Diphosphate Ribose Template

Title CD 38 Structure-Based Inhibitor Design Using the N 1-CyclicInosine 5 ′-Diphosphate Ribose Template

Synthesis of Novel Nilotinib Analogues and Biological Evaluation of Their Antiplatelet Activity and Functionality towards Cancer Cell Proliferation In Vitro

Identification of the platelet ADP receptor targeted by antithrombotic drugs

Clinical pharmacokinetics of ticlopidine

Synthesis of CC, CN coupled novel substituted dibutyl benzothiazepinone derivatives and evaluation of their thrombin inhibitory activity.

Human soluble CD39 displays substrate inhibition in a substrate-specific manner

Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides

Substitutions at the C-8 position of quinazolin-4-ones improve the potency of nicotinamide site binding tankyrase inhibitors

Synthesis and Antitumor Activity of a Novel Series of 6-Substituted Pyrrolo[2,3-D]pyrimidines As Potential Nonclassical Antifolates Targeting Both Thymidylate and Purine Nucleotide Biosynthesis.

QSAR, structure-based pharmacophore modelling and biological evaluation of novel platelet ADP receptor (P2Y12) antagonist